Seo Jin-seok faces defining test at Celltrion

Celltrion's near-term outlook looks solid. The Korean biosimilar giant has just posted its strongest annual earnings on record, underscoring the resilience of its core portfolio. But beyond the upbeat numbers lies a more consequential test. Seo Jin-seok, the 42-year-old CEO and eldest son of founder and Chair Seo Jung-jin, must now prove he can drive Celltrion's next growth engine by advancing its new drug pipelines and expanding its global footprint. In January, Seo stepped onto the main stage

By The Korea Herald